EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Sustained Drug–Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone‐Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide

Yoshihisa Mimura, Takaomi Sanda, Rei Unno iD, Yuki Furukawa, Ryota Shizu, Kotona Motokatsu, Yuusuke Tashiro, Yoshihiko Tasaki, Yosuke Sugiyama, Tomoya Yasujima, Taku Naiki iD, Yasuhiro Horita und 6 weitere

Case Reports in Oncological Medicine · 2026-01 · 2026 (1)

DOI: 10.1155/crom/3539500 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Case Reports in Oncological Medicine, online erschienen am 24.02.2026. Verfasst von Yoshihisa Mimura und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Education, Culture, Sports, Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Apalutamide (Apa) is a key therapeutic agent for prostate cancer. Despite its efficacy, Apa is known to induce several drug‐metabolizing enzymes including cytochrome P450 3A4 (CYP3A4), raising concerns about drug–drug interactions (DDIs). This study reports a rare case of a sustained DDI between Apa and cyclosporine (CsA)—a CYP3A4 substrate—in a patient with metastatic hormone‐sensitive prostate cancer (mHSPC) and primary pure red cell aplasia (PRCA). We further investigated whether Apa could activate pregnane X receptor (PXR), a key nuclear receptor that regulates CYP3A4 expression.

Methods

With informed consent, residual blood samples were used to measure serum Apa concentration. To assess the potential of Apa in activating PXR, a reporter gene assay and a CYP3A4 mRNA induction test were performed. Case Presentation A 75‐year‐old man with mHSPC was treated with Apa and leuprorelin. He developed PRCA and was administered CsA (5 mg/kg/day) on Day 1. Despite a target trough concentration ( C trough ) of 150–200 ng/mL, the C trough of CsA remained subtherapeutic (34 ng/mL on Day 5), even after dose escalation to 10 mg/kg/day ( C trough : 66 ng/mL on Day 7), suspecting a DDI with Apa. On Day 8, Apa was discontinued and the CsA dosage was reduced to 5 mg/kg/day. The Apa concentrations measured on Days 13, 26, and 34 were 1.1, 0.15, and 0.07 μ g/mL, respectively, and the C trough of CsA increased to 45, 82, and 134 ng/mL, respectively. In vitro experiments demonstrated that Apa was a strong activator of PXR and capable of inducing CYP3A4 .

Conclusion

Apa induced CYP3A4 via the PXR pathway, leading to a sustained DDI with CsA. Careful monitoring is necessary when Apa is coadministered with CYP3A4 substrates.

Schlagwörter

Stichwörter der Autor:innen

apalutamidecyclosporinecytochrome P450 3A4drug–drug interactionspregnane X receptor

Autor:innen und Institutionen

  • Department of Clinical Pharmaceutics, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp.
  • Department of Hematology and Oncology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp.
  • Department of Nephro-urology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan, nagoya-cu.ac.jp.
  • Laboratory of Molecular Toxicology, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Shizuoka, Japan, u-shizuoka-ken.ac.jp.
  • Department of Biopharmaceutics, Nagoya City University Graduate School of Pharmaceutical Sciences, Nagoya, Aichi, Japan.

ORCID-Profile: Rei Unno, Taku Naiki, Yoko Furukawa-Hibi

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology

Zitieren

APA

Mimura, Y., Sanda, T., Unno, R., Furukawa, Y., Shizu, R., Motokatsu, K., Tashiro, Y., Tasaki, Y., Sugiyama, Y., Yasujima, T., Naiki, T., Horita, Y., Hotta, Y., Yuasa, H., Yoshinari, K., Yasui, T., Iida, S., & Furukawa-Hibi, Y. (2026). Sustained Drug–Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone‐Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide. Case Reports in Oncological Medicine, 2026(1). https://doi.org/10.1155/crom/3539500

Vancouver

Mimura Y, Sanda T, Unno R, Furukawa Y, Shizu R, Motokatsu K, et al. Sustained Drug–Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone‐Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide. Case Reports in Oncological Medicine. 2026;2026(1). doi:10.1155/crom/3539500

BibTeX
@article{Mimura2026,
  author = {Mimura, Yoshihisa and Sanda, Takaomi and Unno, Rei and Furukawa, Yuki and Shizu, Ryota and Motokatsu, Kotona and Tashiro, Yuusuke and Tasaki, Yoshihiko and Sugiyama, Yosuke and Yasujima, Tomoya and Naiki, Taku and Horita, Yasuhiro and Hotta, Yuji and Yuasa, Hiroaki and Yoshinari, Kouichi and Yasui, Takahiro and Iida, Shinsuke and Furukawa-Hibi, Yoko},
  title = {Sustained Drug–Drug Interaction Between Cyclosporine and Apalutamide in a Patient With Metastatic Hormone‐Sensitive Prostate Cancer: A Case Report and Evaluation of CYP3A4 Induction via Pregnane X Receptor Activation by Apalutamide},
  journal = {Case Reports in Oncological Medicine},
  year = {2026},
  volume = {2026},
  number = {1},
  doi = {10.1155/crom/3539500}
}
Kostenlos starten →